Truist analyst Joon Lee initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics Aligns Executive Incentives with Milestones
- Market ‘misinterpreting’ Larimar data, selloff ‘overdone,’ says Citi
- Larimar Therapeutics selloff a buying opportunity, says JonesResearch
- Larimar Therapeutics trading resumes
- Larimar Therapeutics trading halted, volatility trading pause